Sangamo Therapeutics, Inc.
 
公司簡況
財務
派息紀錄
盈利預測
股權變動
ETF簡況
 
 
 
公司概覽
業務類別 --
業務概覽 Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its neurology development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases and development of novel engineered adeno-associated virus, or AAV, capsids to deliver its therapies to the intended neurological targets. The group's pipeline products are Small Fiber Neuropathy, Prion Disease, Tauopathies, ALS/FTD, Huntington's Disease, Fabry Disease, and Hemophilia A.
公司地址 501 Canal Boulevard, Richmond, CA, USA, 94804
電話號碼 +1 510 970-6000
傳真號碼 +1 510 236-8951
公司網頁 https://www.sangamo.com
員工數量 142
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. Alexander Donald Macrae, M.B.,PhD Director, President and Chief Executive Officer 美元 716.37K 30/03/2026
Ms. Prathyusha Duraibabu Chief Financial Officer and Principal Accounting Officer 美元 483.96K 11/09/2025
Mr. Rolf Andrew Ramelmeier, PhD Executive Vice President, Technical Operations 美元 432.64K 26/04/2023
Mr. David Mark McClung Executive Vice President and Chief Operating Officer 美元 493.50K 17/04/2023
Mr. Robert J. Schott, F.A.C.C.,M.D.,M.P.H. Senior Vice President and Head of Development 美元 397.69K 09/08/2022
Mr. Jason D. Fontenot, PhD Senior Vice President and Chief Scientific Officer 美元 474.24K 17/04/2023
Mr. Scott B. Willoughby General Counsel and Corporate Secretary -- 30/04/2025
Ms. Nathalie Dubois-Stringfellow, PhD Chief Development Officer 美元 453.60K 30/04/2025
Mr. Phillip Ramsey Head of Technical Operations -- 26/04/2023
Ms. Amy Pooler, PhD Vice President and Head of Research -- 19/04/2024
Mr. Gregory Davis, PhD Head of Research and Technology -- 30/04/2025
Mr. Nikunj Jain Interim Chief Financial Officer, Principal Accounting Officer, Vice President, Finance and Corporate Controller -- 03/02/2026
 
董事會成員
董事會 職務 更新日期
Ms. H. Stewart Parker Chairwoman of the Board 30/03/2026
Mr. James R. Meyers Independent Director 30/03/2026
Mr. Joseph S. Zakrzewski Independent Director 24/02/2022
Ms. Margaret A. Horn, J.D. Independent Director 30/03/2026
Ms. Saira Ramasastry Independent Director 01/04/2022
Mr. Robert F. Carey Independent Director 30/03/2026
Dr. Kenneth J. Hillan, Ch.B.,M.B. Independent Director 30/03/2026
Dr. Karen L. Smith, L.L.M.,M.B.A.,M.D.,PhD Independent Director 30/03/2026
Dr. Alexander Donald Macrae, M.B.,PhD Director, President and Chief Executive Officer 30/03/2026
Dr. John H. Markels, PhD Independent Director 30/03/2026
Ms. Courtney Beers, PhD Independent Director 30/03/2026
 
所屬ETF (更新日期: 25/06/2026 02:25)
代號 名稱 佔比% ▼ 持有日期
PRFZInvesco FTSE RAFI US 1500 Small-Mid ETF0.11%28/02/2025
FESMFidelity® Enhanced Small Cap ETF0.10%29/12/2023
QQQSInvesco NASDAQ Patent Innovators ETF0.01%31/05/2023
SQLVLegg Mason Small-Cap Quality Value ETF0.003%17/09/2021
GUGGuggenheim Active Allocation Fund0.0003%30/11/2025
STXKStrive 2000 ETF0.0001%30/12/2022
AIEQAI Powered Equity ETF<0.000001%24/06/2022
AVSCAvantis US Small Cap Equity ETF<0.000001%17/01/2025
AVSCAvantis® US Small Cap Equity ETF<0.000001%01/06/2023
AVUSAvantis US Equity ETF<0.000001%01/06/2023
AVUSAvantis® U.S. Equity ETF<0.000001%01/06/2023
AVUVAvantis® U.S. Small Cap Value ETF<0.000001%12/10/2021
BBCVirtus LifeSci Biotech Clinical Trls ETF<0.000001%16/06/2023
BBSCJPMorgan BetaBuilders US Sml Cp Eq ETF<0.000001%20/06/2023
BIBProShares Ultra Nasdaq Biotechnology<0.000001%18/12/2023
DFACDimensional US Core Equity 2 ETF<0.000001%24/11/2023
DFASDimensional US Small Cap ETF<0.000001%13/10/2023
DFATDimensional US Targeted Value ETF<0.000001%03/10/2023
DFAUDimensional US Core Equity Market ETF<0.000001%14/08/2023
DFSUDimensional US Sustainability Core 1 ETF<0.000001%14/08/2023
 1    2    3    4    5  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.